MARKET

SRRK

SRRK

Scholar Rock Holding
NASDAQ
41.94
-0.25
-0.59%
Pre Market: 41.94 0 0.00% 04:00 10/13 EDT
OPEN
41.94
PREV CLOSE
42.19
HIGH
42.52
LOW
41.38
VOLUME
20
TURNOVER
0
52 WEEK HIGH
61.76
52 WEEK LOW
27.07
MARKET CAP
5.11B
P/E (TTM)
-12.6173
1D
5D
1M
3M
1Y
5Y
1D
Could Scholar Rock Holding (SRRK) Be Closer To Europe After Its Apitegromab Refiling?
Simply Wall St · 3h ago
Scholar Rock Holding (SRRK) Receives a Buy from BMO Capital
TipRanks · 20h ago
Weekly Report: what happened at SRRK last week (1005-1009)?
Weekly Report · 23h ago
Analysts Offer Insights on NA Companies: Scholar Rock Holding (SRRK) and Strategy (MSTR)
TipRanks · 4d ago
Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval
NASDAQ · 4d ago
Scholar Rock Resubmits Marketing Authorisation Application For Apitegromab
NASDAQ · 4d ago
Scholar Rock resubmits MAA for apitegromab to the EMA
TipRanks · 4d ago
Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spinal Muscular Atrophy
Benzinga · 4d ago
More
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.

Webull offers Scholar Rock Holding Corp stock information, including NASDAQ: SRRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRRK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRRK stock methods without spending real money on the virtual paper trading platform.